R C G Bruijnen
Overview
Explore the profile of R C G Bruijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andel D, Ramdhani K, Braat A, Bruijnen R, Bol G, Keane G, et al.
Cardiovasc Intervent Radiol
. 2024 Nov;
48(3):379-385.
PMID: 39604694
Purpose: To describe the outcome of radiation lobectomy (RL) after double vein embolization (portal vein embolization + hepatic vein embolization) for patients with insufficient future liver remnant growth. Materials And...
2.
Ramdhani K, Beijer-Verduin J, Ebbers S, van Rooij R, Smits M, Bruijnen R, et al.
Eur J Nucl Med Mol Imaging
. 2024 Feb;
51(7):2114-2123.
PMID: 38369678
Purpose: Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM) treated with holmium-166-microspheres...
3.
Korenblik R, Olij B, Aldrighetti L, Abu Hilal M, Ahle M, Arslan B, et al.
Cardiovasc Intervent Radiol
. 2022 Jul;
45(9):1391-1398.
PMID: 35790566
Study Purpose: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients...
4.
Alsultan A, Braat A, Smits M, Barentsz M, Bastiaannet R, Bruijnen R, et al.
Clin Oncol (R Coll Radiol)
. 2020 Dec;
33(2):106-116.
PMID: 33358630
Radioembolisation is a locoregional treatment modality for hepatic malignancies. It consists of several stages that are vital to its success, which include a pre-treatment angiographic simulation followed by nuclear medicine...
5.
Buisman F, Homs M, Grunhagen D, Filipe W, Bennink R, Besselink M, et al.
BMC Cancer
. 2019 Apr;
19(1):327.
PMID: 30953467
Background: Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP)...
6.
Parry K, Haverkamp L, Bruijnen R, Siersema P, Offerhaus G, Ruurda J, et al.
Eur J Surg Oncol
. 2016 Jan;
42(3):400-6.
PMID: 26777127
Background: Clinical staging of adenocarcinoma of the gastroesophageal junction (GEJ) determines the curative treatment regimen containing either neoadjuvant chemotherapy or chemoradiotherapy followed by either gastrectomy or esophagectomy. The value of...
7.
Parry K, Haverkamp L, Bruijnen R, Siersema P, Ruurda J, van Hillegersberg R
Ann Surg Oncol
. 2014 Sep;
22(2):597-603.
PMID: 25190126
Background: Patients with adenocarcinoma of the gastro-esophageal junction (GEJ) may undergo either esophagectomy or gastrectomy. The aim of this study was to evaluate the outcome of surgical therapy with regard...